<DOC>
	<DOCNO>NCT00002745</DOCNO>
	<brief_summary>Phase II trial study effectiveness aminocamptothecin treat patient refractory recurrent Hodgkin 's disease non-Hodgkin 's lymphoma . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Aminocamptothecin Treating Patients With Refractory Recurrent Hodgkin 's Disease Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response rate duration response aminocamptothecin ( 9-AC ) patient refractory relapsed Hodgkin 's disease non-Hodgkin 's lymphoma . II . Assess toxicity 9-AC patient . III . Validate preliminary pharmacodynamic model relate total 9-AC concentration , albumin , bilirubin toxicity . IV . Determine whether 9-AC concentration correlate response . OUTLINE : Patients stratify disease histology ( International Working Formulation ( IWF ) A-C v IWF D-F ) center . Patients receive aminocamptothecin IV continuously day 1-3 . Treatment repeat every 2 week minimum 3 course absence disease progression unacceptable toxicity . Patients achieve stable disease , partial response ( PR ) , complete response ( CR ) may receive 2 additional course past best response ( minimum 6 course PR CR ) . Patients follow every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document Hodgkin 's disease ( close accrual 4/15/2000 ) OR Histologically document nonHodgkin 's lymphoma ( NHL ) one follow International Working Formulation ( IWF ) histology : Small lymphocytic ( absolute lymphocyte count le 5,000 ) IWF A Follicular , predominantly small cleave cell IWF B Follicular mix IWF C Follicular large cell IWF D* Diffuse small cleave cell IWF E* Diffuse mixed IWF F* Diffuse large cell IWF G* Large cell , immunoblastic IWF H* * Accrual patient diagnosis close 4/15/2000 Pathology review require within 60 day registration Refractory relapse prior chemotherapy follow : Lowgrade NHL ( IWF AC ) : 1 2 prior therapy Intermediategrade NHL ( IWF DH ) : 1 prior therapy ( stratum close 4/15/2000 ) Hodgkin 's disease : 1 2 prior therapy ( stratum close 4/15/2000 ) Treatment drug 2 different schedule consider 1 therapy Measurable disease physical exam image study Mass large 1 x 1 cm Documented progression require previously irradiate lesion The following consider measurable : Ascites pleural effusion Bone marrow involvement Positive barium study Bony disease ( lytic lesion note ) No mantle cell transform lymphoma No parenchymal leptomeningeal CNS disease A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : CALGB 02 Unless hypersplenism biopsyproven bone marrow involvement : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Bilirubin normal AST great 4 time normal Creatinine normal No suspect HIV infection No second malignancy within past 5 year except : Curatively treat carcinoma cervix Curatively treat basal cell skin cancer No uncontrolled infection serious medical condition No psychiatric condition precludes inform consent Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior allogeneic autologous bone marrow transplant More 3 week since chemotherapy ( 6 week since nitrosoureas , melphalan , mitomycin ) No prior camptothecin More 3 week since radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
</DOC>